Formulation and Specifications: Hard Capsules: 1mg, 5mgIndications: This single agent is indicated for patients with metastatic colorectal cancer (mCRC) who have received prior fluorouracil-based, oxaliplatin and irinotecan-based chemotherapy and who…
Formulation and specifications: Injection: 100mg (20ml)/bottleIndications: For the treatment of metastatic colorectal cancer with RAS, BRAF gene wild type: in combination with FOLFOX or FOLFIRI regimen for first-line treatment; in…
Formulation and specifications: Injection: 100mg (4ml)/bottleIndications:1. Bevacizumab in combination with fluorouracil-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.2. Bevacizumab in combination with atelelizumab for the…
Formulation and Specifications: Capsules: 50 mgIndications: Non-pancreatic-derived neuroendocrine tumors of good differentiation (Gl, G2) of localized late stage or metastatic, progressive stage that are not surgically resectable.Key points for rational…
Formulation and Specifications: Tablets: 2.5mg, 5mg, 10mgIndications: Adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or highly differentiated) progressive pancreatic neuroendocrine tumors; adult patients with unresectable, locally advanced…
Formulation and Specifications: Tablets: 50 mgIndications: Treatment of adult patients with advanced gastrointestinal mesenchymal tumors who have received 3 or more prior tyrosine kinase inhibitors (including imatinib).Rational Dosing Points:1. The…
Formulation and Specifications: Tablets: 100mg, 200mg, 300mgIndications: Treatment of adult patients with unresectable or metastatic gastrointestinal mesenchymal tumors carrying platelet-derived growth factor receptor a (PDGFRA) exon 18 mutations, including the…
Formulation and specifications: Capsules: 12.5mg, 25mg, 37.5mg, 50mgIndications:1. Patients with gastrointestinal mesenchymal tumors who have failed or are intolerant to imatinib therapy.2. Adult patients with unresectable, metastatic highly differentiated progressive…
Formulation and specifications: (1) Tablets: 100mg, 400mg; (2) Capsules: 50mg, 100mgIndications:1. For the treatment of adult patients with unresectable and/or metastatic gastrointestinal mesenchymal tumors.2. For the adjuvant treatment of adult…
Formulation and specifications: Lyophilized formulation: 60 mg/stemIndications: Patients with HER2 overexpression in locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least 2 systemic chemotherapies.…